Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AMX-201
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : DIMERx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
DIMERx Secures Global Rights to Novel Amino Acid Prodrug Developed at MGH
Details : Under the term of license agreement, DIMERx aims to advance the development of AMX-201, currently being evaluated in early-stage trials for treating challenging paradigms across various rare diseases.
Product Name : AMX-201
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : AMX-201
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : DIMERx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : SYN-020
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Theriva Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : SYN-020 is a recombinant bovine Intestinal Alkaline Phosphatase (IAP) formulated for oral delivery to the small intestine. The amended agreement include intellectual property and technology related to the use of SYN-020 intestinal alkaline phosphatase.
Product Name : SYN-020
Product Type : Enzyme
Upfront Cash : Undisclosed
March 08, 2021
Lead Product(s) : SYN-020
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Theriva Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : SYN-020
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Theriva Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020
Details : Under the terms of the agreement, Synthetic Biologics is granted exclusive rights to negotiate a worldwide license with MGH to commercially develop SYN-020 to treat and prevent metabolic and inflammatory diseases associated with aging.
Product Name : SYN-020
Product Type : Enzyme
Upfront Cash : Undisclosed
May 27, 2020
Lead Product(s) : SYN-020
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Theriva Biologics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : AAVCOVID
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The AAVCOVID Vaccine Program is a unique, gene-based vaccine strategy that uses adeno-associated viral (AAV) vector, a clinically established gene transfer technology leveraging the properties of a harmless viral carrier.
Product Name : AAVCOVID
Product Type : Vaccine
Upfront Cash : Inapplicable
May 05, 2020
Lead Product(s) : AAVCOVID
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vedolizumab
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Royalty Pharma
Deal Size : $94.0 million
Deal Type : Acquisition
Royalty pharma acquires royalties on Entyvio from Massachusetts General Hospital
Details : Through transactions such as this, Royalty Pharma is furthering our goal of accelerating innovation and making the life sciences research and development ecosystem more efficient and productive.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
May 03, 2020
Lead Product(s) : Vedolizumab
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Royalty Pharma
Deal Size : $94.0 million
Deal Type : Acquisition
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Mallinckrodt Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Mallinckrodt to Fund Nitric Oxide Therapy Trial in Covid-19 Patients
Details : Mallinckrodt's support to Massachusetts General Hospital includes providing funding as well as INOmax® (nitric oxide) gas, for inhalation, to facilitate the study.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 30, 2020
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Mallinckrodt Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Theratechnologies
Deal Size : Undisclosed
Deal Type : Agreement
Theratechnologies Ink Agreements with General Hospital Massachusetts
Details : Theratechnologies Inc. signed of long-term agreements with the MGH towards the development of tesamorelin for the treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.
Product Name : Tesamorelin F8
Product Type : Hormone
Upfront Cash : Undisclosed
April 02, 2020
Lead Product(s) : Tesamorelin Acetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Theratechnologies
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Abemaciclib
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : National Comprehensive Cancer Network
Deal Size : Undisclosed
Deal Type : Funding
Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly Oncology
Details : The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announced five projects selected to receive funding for clinical and preclinical evaluation of abemaciclib.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 12, 2020
Lead Product(s) : Abemaciclib
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : National Comprehensive Cancer Network
Deal Size : Undisclosed
Deal Type : Funding